-- Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older -- Results consistent with Phase 3 LAVENDER™ and open-label LILAC™ ...
(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) announced the publication of clinical data from the open-label DAFFODIL study, which evaluated the long-term safety and efficacy of DAYBUE or trofinetide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results